UBS Group AG decreased its position in shares of PetMed Express, Inc. (NASDAQ:PETS) by 20.5% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 79,960 shares of the company’s stock after selling 20,672 shares during the period. UBS Group AG owned about 0.39% of PetMed Express worth $1,610,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Westside Investment Management Inc. raised its stake in PetMed Express by 15.8% in the first quarter. Westside Investment Management Inc. now owns 5,502 shares of the company’s stock valued at $114,000 after buying an additional 752 shares during the last quarter. Group One Trading L.P. acquired a new stake in PetMed Express during the first quarter valued at $174,000. Arizona State Retirement System raised its stake in PetMed Express by 0.9% in the first quarter. Arizona State Retirement System now owns 10,667 shares of the company’s stock valued at $215,000 after buying an additional 100 shares during the last quarter. Thrivent Financial For Lutherans raised its stake in PetMed Express by 4.1% in the first quarter. Thrivent Financial For Lutherans now owns 11,530 shares of the company’s stock valued at $232,000 after buying an additional 450 shares during the last quarter. Finally, Thrivent Financial for Lutherans raised its stake in PetMed Express by 5.8% in the fourth quarter. Thrivent Financial for Lutherans now owns 11,080 shares of the company’s stock valued at $256,000 after buying an additional 610 shares during the last quarter. 78.36% of the stock is currently owned by institutional investors and hedge funds.

PetMed Express, Inc. (NASDAQ PETS) traded up 0.63% during trading on Tuesday, reaching $48.23. The company had a trading volume of 430,357 shares. PetMed Express, Inc. has a 52-week low of $18.90 and a 52-week high of $50.90. The company has a market capitalization of $978.68 million, a PE ratio of 37.10 and a beta of 0.99. The company has a 50 day moving average price of $41.47 and a 200 day moving average price of $28.88.

PetMed Express (NASDAQ:PETS) last issued its quarterly earnings results on Monday, July 24th. The company reported $0.45 EPS for the quarter, beating the Zacks’ consensus estimate of $0.38 by $0.07. The company had revenue of $79.66 million during the quarter, compared to the consensus estimate of $77.32 million. PetMed Express had a return on equity of 28.67% and a net margin of 10.34%. PetMed Express’s revenue was up 9.9% on a year-over-year basis. During the same period last year, the business posted $0.32 earnings per share. On average, equities analysts forecast that PetMed Express, Inc. will post $1.44 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, August 18th. Shareholders of record on Monday, August 7th will be given a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 1.66%. The ex-dividend date is Thursday, August 3rd. PetMed Express’s dividend payout ratio is currently 61.54%.

COPYRIGHT VIOLATION NOTICE: “PetMed Express, Inc. (PETS) Shares Sold by UBS Group AG” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://www.thecerbatgem.com/2017/08/08/petmed-express-inc-pets-stake-decreased-by-ubs-group-ag-updated-updated-updated.html.

PETS has been the subject of several recent research reports. Zacks Investment Research raised shares of PetMed Express from a “sell” rating to a “hold” rating in a report on Wednesday, April 12th. Craig Hallum downgraded shares of PetMed Express from a “buy” rating to a “hold” rating in a report on Tuesday, July 11th. Northcoast Research raised shares of PetMed Express from a “neutral” rating to a “buy” rating and set a $54.00 price target for the company in a report on Monday, July 24th. Finally, Noble Financial reaffirmed a “hold” rating on shares of PetMed Express in a research note on Wednesday, July 26th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $35.00.

In other news, Director Robert C. Schweitzer sold 2,500 shares of PetMed Express stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $49.18, for a total value of $122,950.00. Following the completion of the transaction, the director now directly owns 88,834 shares in the company, valued at $4,368,856.12. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Ronald J. Korn sold 5,000 shares of PetMed Express stock in a transaction on Friday, July 28th. The shares were sold at an average price of $48.18, for a total value of $240,900.00. Following the completion of the transaction, the director now owns 67,333 shares of the company’s stock, valued at $3,244,103.94. The disclosure for this sale can be found here. Insiders sold 59,333 shares of company stock valued at $2,254,030 over the last three months. Company insiders own 4.00% of the company’s stock.

About PetMed Express

PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.

Institutional Ownership by Quarter for PetMed Express (NASDAQ:PETS)

Receive News & Stock Ratings for PetMed Express Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express Inc. and related stocks with our FREE daily email newsletter.